SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas

The goal of this clinical trial is to learn what dose of the drug SB-4826 can be given safely in patients with solid tumors and non-Hodgkin lymphomas. This drug will be used alone in patients with solid tumors, and will be used alone or in combination with rituximab in patients with non-Hodgkin lymphomas. The main questions this clinical trial aims to answer are: What is the maximum dose of SB-4826 that can be used safely in patients with solid tumors and non-Hodgkin lymphomas, and will it work? How does SB-4826 work in people with cancer? How is SB-4826 absorbed, broken down, and excreted by the body? Participants will: Take drug SB-4826 twice weekly for up to 1 year; keep a diary of when they take SB-4826 at home; visit the clinic for checkups, tests, and fill out study questionnaires.

NCT Number	NCT07222631
Lead Sponsor	University of California, San Diego Collaborators: The Institute for Follicular Lymphoma Innovation
Conditions	Non Hodgkin Lymphoma, Solid Tumor
Enrollment	48 participants
Start Date	2026-02-18
Primary Completion	2031-02 (estimated)
Study Completion	2033-02 (estimated)
Updated on ClinicalTrials.gov	2026-03-05